Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

被引：7

作者：

Villalba, Ana ^{[1
]}

Pilar Gonzalez-Rodriguez, Ana ^{[2
]}

Arzuaga-Mendez, Javier ^{[3
]}

Puig, Noemi ^{[4
]}

Arnao, Mario ^{[1
]}

Maria Arguinano, Jose ^{[5
]}

Jimenez, Maria ^{[6
]}

Canet, Marta ^{[7
]}

Teruel, Ana, I ^{[8
]}

Sola, Maria ^{[9
]}

Diaz, Francisco J. ^{[10
]}

Encinas, Cristina ^{[11
]}

Garcia, Antonio ^{[12
]}

Rosinol, Laura ^{[13
]}

Suarez, Alexia ^{[14
]}

Sonia Gonzalez, Marta ^{[15
]}

Izquierdo, Isabel ^{[16
]}

Teodoro Hernandez, Miguel ^{[17
]}

Stefania Infante, Maria ^{[18
]}

Jose Sanchez, Maria ^{[19
]}

Sampol, Antonia ^{[20
]}

de la Rubia, Javier ^{[1
,21
,22
]}

机构：

[1] Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

[2] Hosp Univ Cent Asturias HUCA Oviedo, Hematol Dept, Oviedo, Spain

[3] Hosp Univ Cruces, Biocruces Bizkaia Hlth Res Inst, Hematol Dept, Grp Canc Hematol, Baracaldo, Spain

[4] Hosp Univ Salamanca HUSAL, Hematol Dept, CIBERONC, IBMCC USAL CSIC,IBSAL, Salamanca, Spain

[5] Complejo Hosp Navarra, Hematol Dept, Pamplona, Spain

[6] Hosp Univ Dr Peset, Hematol Dept, Valencia, Spain

[7] Hosp Univ Mutua Terrasa, Hematol Dept, Terrassa, Spain

[8] Hosp Clin Univ, Hematol Dept, Valencia, Spain

[9] Hosp Univ Morales Meseguer, Hematol Dept, Murcia, Spain

[10] Hosp Univ Burgos, Hematol Dept, Burgos, Spain

[11] Hosp Gen Univ Gregorio Maranon HGUGM, Hematol Dept, IiSGM, Madrid, Spain

[12] Hosp Arnau Vilanova, Hematol Dept, Lleida, Spain

[13] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain

[14] Hosp Gran Canaria Doctor Negrin, Hematol Dept, Las Palmas Gran Canaria, Municipality Of, Spain

[15] H Clin Univ Santiago Compostela, Hematol Dept, La Coruna, Spain

[16] Hosp Univ Miguel Servet, Hematol Dept, Zaragoza, Spain

[17] Hosp Univ Canarias, Hematol Dept, Santa Cruz De Tenerife, Spain

[18] Hosp Univ Infanta Leonor, Hematol Dept, Madrid, Spain

[19] Hosp Univ Lucus Augusti, Hematol Dept, Lugo, Spain

[20] Hosp Univ Son Espases, Hematol Dept, Palma De Mallorca, Spain

[21] Univ Catolica San Vicente Martir, Hematol Dept, Valencia, Spain

[22] CIBERONC CB16-12-00284, Valencia, Spain

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 14期

关键词：

Multiple myeloma; autologous stem cell transplantation; high-risk cytogenetics; tandem transplantation; MINIMAL RESIDUAL DISEASE; DEXAMETHASONE; BORTEZOMIB; LENALIDOMIDE; SURVIVAL; CRITERIA; THERAPY; MAINTENANCE; MELPHALAN; CONSENSUS;

D O I：

10.1080/10428194.2022.2123229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having >= 1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10-82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic.

引用

页码：3438 / 3447

页数：10

共 50 条

[21] A retrospective analysis of upfront tandem autologous stem cell transplantation (ASCT) for high-risk (HR) myeloma (MM) patients (Pts).
Zarabi, Sara Farshchi
Parmar, Gurdeep
Masih-Khan, Esther
Farooki, Sophia
Chen, Christine
Kukreti, Vishal
Prica, Anca
Tiedemann, Rodger
Trudel, Suzanne
Reece, Donna Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[22] Update of autologous-allogeneic tandem stem cell transplantation in patients with newly diagnosed multiple myeloma with emphasis on unrelated donors
Kröger, N
Sayer, HG
Schwerdtfeger, R
Zabelina, T
Ayuk, F
Shimoni, A
Nagler, A
Perez-Simon, JA
San Miguel, JF
Zander, AR
EXPERIMENTAL HEMATOLOGY, 2004, 32 (07) : 80 - 80
[23] Impact of high-risk cytogenetics in newly diagnosed multiple myeloma undergoing upfront stem cell transplantation: A study from the EBMT chronic malignancies working party
Gagelmann, Nico
Eikema, Dirk-Jan
Iacobelli, Simona
Maertens, Johan
Koster, Linda
Caillot, Denis
Blaise, Didier
Rememyi, Peter
Bulabois, Claude-Eric
Passweg, Jakob
Leleu, Xavier
Zver, Samo
Kobbe, Guido
Rambaldi, Alessandro
Nahi, Hareth
Chevallier, Patrice
Ringhoffer, Mark
Martin, Alexander M.
Salmenniemi, Urpu
Poire, Xavier
Lenhoff, Stig
Pioltelli, Pietro
Mordini, Nicola
Schoenland, Stefan
Garderet, Laurent
Yakoub-Agha, Ibrahim
Kroeger, Nicolaus
BONE MARROW TRANSPLANTATION, 2019, 54 : 118 - 119
[24] SUPERIOR EFFICACY OF VTD OVER VCD BEFORE AND AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Cavo, M.
Pantani, L.
Pezzi, A.
Gay, F.
Petrucci, M. T.
Patriarca, F.
Zamagni, E.
Vincelli, D.
Carella, A. M.
Tacchetti, P.
Testoni, N.
Di Bartolomeo, P.
Caravita, T.
Cafro, A. M.
Gabbas, A.
Ameli, G.
Rizzi, R.
Cantore, N.
Morabito, F.
Sonneveld, P.
Palumbo, A.
HAEMATOLOGICA, 2015, 100 : 516 - 516
[25] Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation
Ma, Kewa
Ye, Jiannan
Wang, Lingling
Sun, Chao
Zhou, Xin
ONCOTARGETS AND THERAPY, 2021, 14 : 2349 - 2361
[26] Outcome of Autologous Stem Cell Transplantation in High-Risk Multiple Myeloma: A Single-Center Experience
Pincha, Rajat
Ghosh, Shouriyo
Podder, Dibakar
Kumar, Jeevan
Nag, Arijit
Javed, Rizwan
Chattopadhyay, Debranjani
Mishra, Deepak
Parihar, Mayur
Nair, Reena
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S565 - S565
[27] Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma
Garifullin, Andrey
Voloshin, Sergei
Shuvaev, Vasily
Martynkevich, Irina
Kleina, Elizaveta
Chechetkin, Alexander
Bessmeltcev, Stanislav
Kuzyaeva, Anastasiya
Hmidt, Alexander S.
Kuvshinov, Alexey
Pavlova, Irina
BLOOD, 2019, 134
[28] High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Cook, Gordon
Williams, Cathy
Brown, Julia M.
Cairns, David A.
Cavenagh, Jamie
Snowden, John A.
Ashcroft, A. John
Fletcher, Marie
Parrish, Chris
Yong, Kwee
Cavet, Jim
Hunter, Hanna
Bird, Jenny M.
Chalmers, Anna
O'Connor, Sheila
Drayson, Mark T.
Morris, Treen C. M.
LANCET ONCOLOGY, 2014, 15 (08): : 874 - 885
[29] Outcomes of Single Versus Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience
Philip, Shona
Dehghani, Mina
Siqueira, Lenicio
Quint, Anthony
Lam, Selay
Phua, Chai Wye
Xenocostas, Anargyros
Deotare, Uday
Louzada, Martha L.
BLOOD, 2021, 138
[30] Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study
Kalff, Anna
Kennedy, Nola
Smiley, Angela
Prince, H. Miles
Roberts, Andrew W.
Bradstock, Kenneth
De Abreu Loureno, Richard
Frampton, Chris
Spencer, Andrew
LANCET HAEMATOLOGY, 2014, 1 (03): : E112 - E119

← 1 2 3 4 5 →